Drug Evaluation Committee RMP training slides for MRs (revised August 2025)
Pharmacovigilance Subcommittee
October 2025
Japan Pharmaceutical Manufacturers Association, Drug Evaluation Committee
Pharmacovigilance Subcommittee, Continuing Issues Response Team 1 (KT1)
Aiming at the development of a system for drug risk management planning, the Drug Evaluation Committee PV Subcommittee Continuing Issues Response Team has so far published "RMP Training Slides for MRs" and "RMP Explanation Slides by MRs (Slide Template for RMP Explanation for Medical Institutions)" in March, 2025.
More than 10 years have passed since the system of drug risk management plans (RMPs) came into effect in Japan, and surveys have shown that pharmacists' recognition and utilization of RMPs have also progressed. On the other hand, there are some cases where MRs are promoting drugs with little regard for side effects and safety.
The JPMA Code of Practice will be revised in May 2025, and the code clearly states that MRs are required to acquire knowledge and provide appropriate information to healthcare professionals not only about electronic dossiers but also about RMPs.
We have revised the "RMP Training Slide for MRs" to help them understand how important it is to provide information based on RMPs to healthcare professionals. We hope that the effective use of these slides by pharmaceutical companies will further promote the provision of RMP-based information by MRs to healthcare professionals.